OCUGEN, INC. Weighted Average Number of Shares Outstanding, Basic and Diluted
OCUGEN, INC. (OCGN) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 186.30 million shares for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-07.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2021-05-07
- OCUGEN, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-03-31 was 186.30M shares, a 254.00% increase year-over-year.
- OCUGEN, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-12-31 was 170.65M shares, a 348.43% increase year-over-year.
- OCUGEN, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-09-30 was 141.59M shares, a 2108.46% increase year-over-year.
- OCUGEN, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-06-30 was 83.54M shares, a 1276.82% increase year-over-year.
- OCUGEN, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 112.24M shares, a 707.81% increase from fiscal 2019.
- OCUGEN, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2019 was 13.89M shares, a 180.09% increase from fiscal 2018.
- OCUGEN, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2018 was 4.96M shares.
- OCUGEN, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2015 was 13.23M shares, a 762.46% increase from fiscal 2014.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month as first filed | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month as first filed | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|---|---|
| 2021-03-31 | 186.30M shares 10-Q · filed 2021-05-07 | 178.48M shares derived: average of 2 quarters · filed 2021-05-07 | 166.18M shares derived: average of 3 quarters · filed 2021-05-07 | 145.52M shares derived: average of 4 quarters · filed 2021-05-07 | ||
| 2020-12-31 | 170.65M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19 | 156.12M shares derived: average of 2 quarters · filed 2021-03-19 | 131.93M shares derived: average of 3 quarters · filed 2021-03-19 | 112.24M shares 10-K · filed 2021-03-19 | ||
| 2020-09-30 | 141.59M shares 10-Q · filed 2020-11-06 | 112.56M shares derived: average of 2 quarters · filed 2020-11-06 | 92.76M shares 10-Q · filed 2020-11-06 | 78.95M shares derived: average of 4 quarters · filed 2021-05-07 | ||
| 2020-06-30 | 83.54M shares 10-Q · filed 2020-08-14 | 68.08M shares 10-Q · filed 2020-08-14 | 58.07M shares derived: average of 3 quarters · filed 2021-05-07 | 45.16M shares derived: average of 4 quarters · filed 2021-05-07 | ||
| 2020-03-31 | 52.63M shares 10-Q · filed 2021-05-07 | 45.34M shares derived: average of 2 quarters · filed 2021-05-07 | 32.36M shares derived: average of 3 quarters · filed 2021-05-07 | 25.79M shares derived: average of 4 quarters · filed 2021-05-07 | ||
| 2019-12-31 | 38.06M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19 | 22.23M shares derived: average of 2 quarters · filed 2021-03-19 | 16.84M shares derived: average of 3 quarters · filed 2021-03-19 | 13.89M shares 10-K · filed 2021-03-19 | ||
| 2019-09-30 | 6.41M shares 10-Q · filed 2020-11-06 | 6.24M shares derived: average of 2 quarters · filed 2020-11-06 | 5.84M shares 10-Q · filed 2020-11-06 | 5.60M shares derived: average of 4 quarters · filed 2020-11-06 | ||
| 2019-06-30 | 6.07M shares 10-Q · filed 2020-08-14 | 94.60B shares 10-Q · filed 2019-08-09 | 5.46M shares 10-Q · filed 2020-08-14 | 87.58B shares 10-Q · filed 2019-08-09 | 5.33M shares derived: average of 3 quarters · filed 2020-08-14 | 5.24M shares derived: average of 4 quarters · filed 2020-08-14 |
| 2019-03-31 | 4.96M shares 10-Q · filed 2020-05-08 | 80.48B shares 10-Q · filed 2019-05-15 | 4.96M shares derived: average of 2 quarters · filed 2020-05-08 | 4.96M shares derived: average of 3 quarters · filed 2020-05-08 | 6.31M shares derived: average of 4 quarters · filed 2020-05-08 | |
| 2018-12-31 | 4.96M shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | 4.96M shares derived: average of 2 quarters · filed 2020-03-27 | 6.76M shares derived: average of 3 quarters · filed 2020-03-27 | 4.96M shares 10-K · filed 2020-03-27 | ||
| 2018-09-30 | 4.96M shares 10-Q · filed 2019-11-12 | 7.65M shares derived: average of 2 quarters · filed 2019-11-12 | 4.96M shares 10-Q · filed 2019-11-12 | |||
| 2018-06-30 | 10.35M shares 8-K/A · filed 2019-10-07 | 28.74M shares 10-Q · filed 2018-08-09 | 10.35M shares 8-K/A · filed 2019-10-07 | 28.21M shares 10-Q · filed 2018-08-09 | ||
| 2018-03-31 | 27.67B shares 10-Q · filed 2019-05-15 | 27.67M shares 10-Q · filed 2018-05-10 | ||||
| 2017-09-30 | 22.55M shares 10-Q · filed 2017-11-09 | 22.37M shares derived: average of 2 quarters · filed 2018-08-09 | 22.22M shares 10-Q · filed 2017-11-09 | |||
| 2017-06-30 | 22.18M shares 10-Q · filed 2018-08-09 | 22.05M shares 10-Q · filed 2018-08-09 | ||||
| 2017-03-31 | 21.91M shares 10-Q · filed 2018-05-10 | |||||
| 2016-09-30 | 13.30M shares 10-Q · filed 2017-11-09 | 13.28M shares derived: average of 2 quarters · filed 2017-11-09 | 13.28M shares 10-Q · filed 2017-11-09 | 13.28M shares derived: average of 4 quarters · filed 2017-11-09 | ||
| 2016-06-30 | 13.27M shares 10-Q · filed 2017-08-10 | 13.27M shares 10-Q · filed 2017-08-10 | 13.27M shares derived: average of 3 quarters · filed 2017-08-10 | 13.26M shares derived: average of 4 quarters · filed 2017-08-10 | ||
| 2016-03-31 | 13.27M shares 10-Q · filed 2017-05-11 | 13.27M shares derived: average of 2 quarters · filed 2017-05-11 | 13.26M shares derived: average of 3 quarters · filed 2017-05-11 | 13.25M shares derived: average of 4 quarters · filed 2017-05-11 | ||
| 2015-12-31 | 13.27M shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | 13.25M shares derived: average of 2 quarters · filed 2016-11-10 | 13.24M shares derived: average of 3 quarters · filed 2016-11-10 | 13.23M shares 10-K · filed 2016-03-10 | ||
| 2015-09-30 | 13.24M shares 10-Q · filed 2016-11-10 | 13.23M shares derived: average of 2 quarters · filed 2016-11-10 | 13.22M shares 10-Q · filed 2016-11-10 | 11.00M shares derived: average of 4 quarters · filed 2016-11-10 | ||
| 2015-06-30 | 13.22M shares 10-Q · filed 2016-08-11 | 13.21M shares 10-Q · filed 2016-08-11 | 10.25M shares derived: average of 3 quarters · filed 2016-08-11 | 7.84M shares derived: average of 4 quarters · filed 2016-08-11 | ||
| 2015-03-31 | 13.20M shares 10-Q · filed 2016-05-12 | 8.77M shares derived: average of 2 quarters · filed 2016-05-12 | 6.05M shares derived: average of 3 quarters · filed 2016-05-12 | 4.69M shares derived: average of 4 quarters · filed 2016-05-12 | ||
| 2014-12-31 | 4.34M shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | 2.48M shares derived: average of 2 quarters · filed 2016-03-10 | 1.85M shares derived: average of 3 quarters · filed 2016-03-10 | 1.53M shares 10-K · filed 2016-03-10 | ||
| 2014-09-30 | 617.86K shares 10-Q · filed 2015-11-12 | 606.71K shares derived: average of 2 quarters · filed 2015-11-12 | 598.68K shares 10-Q · filed 2015-11-12 | |||
| 2014-06-30 | 595.55K shares 10-Q · filed 2015-08-12 | 588.94K shares 10-Q · filed 2015-08-12 | ||||
| 2014-03-31 | 582.25K shares 10-Q · filed 2015-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |